Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended follow-up of subcutaneous Bicillin L-A for secondary prophylaxis in rheumatic fever and rheumatic heart disease
ACTRN12624000333516Phase 2Recruiting
- Sponsor
- University of Otago
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of benzylpenicillin in rheumatic fever (RF) and rheumatic heart disease (RHD), sponsored by University of Otago. Primary endpoints: Adherence to long-term high-dose subcutaneous Bicillin L-A and Duration of penicillin concentrations above target threshold. Started Jun 2023; status: recruiting.
02
Drugs
benzylpenicillin
03
Conditions
rheumatic fever (RF)rheumatic heart disease (RHD)
Beyond the preview
Go deeper on ACTRN12624000333516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000333516.